Articles from Vetter Pharma International GmbH

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has announced the development and upcoming launch of the new version of its proprietary V-OVS® syringe closure system.

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has announced the appointment of three senior leaders to take on the role of managing directors alongside Thomas Otto and Peter Soelkner. As of January 1, 2025, Henryk Badack, Titus Ottinger and Carsten Press will join the management team to continue guiding the family-owned CDMO on its path of sustainable growth.

Vetter, a leading global contract development and manufacturing organization (CDMO), announced its plans to move and expand its Development Services site from Skokie, Illinois, to Des Plaines, further investing in its U.S. footprint. Simultaneously, the company plans additional major investment in its commercial business in the state of Saarland, located in the Southwest of Germany bordering France and Luxembourg, to complement its growth and capacity expansions in Ravensburg and Langenargen which are currently underway. This adds more capacity for future customers around the globe as the injectable industry is witnessing a rise in outsourcing development, manufacturing, assembly and packaging needs to CDMOs.

Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has once again been awarded the Best Managed Companies Award, marking its fifth consecutive win. The jury made its selection based on Vetter’s consistency and strength in driving corporate development and its dedication to implementing innovative initiatives across the company to support its growth. The renowned jury panel considered successes across the evaluation categories of strategy, productivity and innovation, culture and commitment, and governance and finance.

Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma, small pharma and overall respondents. The award reaffirms Vetter’s mission to provide the highest possible quality and value for pharma and biotech companies worldwide in their development, manufacturing as well as assembly and packaging of injectables.

Vetter, a leading globally operating contract development and manufacturing organization (CDMO) announces the successful commercialization of eight customer drug products as of the completion of 2023. The products were supported by the comprehensive portfolio of the Vetter Development Service during their drug development phases. The drug products that reached the world market are used in oncology and to treat autoimmune and cardiovascular diseases, among others. Their nature and administration vary widely, ranging from emergency medications to long-term and life-enhancing therapies for patients. The drugs also vary in delivery methods, which include self-administration for at-home care and administration by healthcare professionals.

Vetter, a leading globally operating contract development and manufacturing organization (CDMO), has joined the German Association of Research-Based Pharmaceutical Companies (vfa) as an associate member. With this membership, the vfa recognizes the significant role that the pharmaceutical service provider plays in the field of complex injectable drugs. Vetter supports research-based pharmaceutical companies worldwide in successfully developing, launching, and establishing their products on the market through the joint development of patient-friendly drug-delivery systems, innovative and flexible filling processes, and packaging solutions. Currently at 48 member companies, the vfa represents more than two thirds of the entire German pharmaceutical market. The companies employ around 94,000 people in Germany. More than 20,000 of them work in the research and development of medicinal products.

Vetter, a leading globally operating Contract Development and Manufacturing Organization (CDMO), has joined the Science Based Targets Initiative (SBTi) membership group as of November 2023. The goal of the companies in the SBTi is to achieve climate neutrality by 2050, thus representing the strictest climate protection targets for companies worldwide. As a result, Vetter has committed to the 1.5 degrees of global warming target. To this end, the CDMO has presented a sustainability strategy with concrete steps to take through 2030, in which the effects of the planned dynamic growth related to CO2 emissions are already factored in. With the commissioning of the new photovoltaic plant and the conversion of another existing combined heat and power plant to biogas, both at its Ravensburg Center for Visual Inspection and Logistics, Vetter is already taking important steps towards Net Zero in 2023.

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has received the permanent Manufacturer’s Authorization for its clinical development site in Rankweil, Austria. Operational for nearly two years, the responsible national regulatory authority, the Austrian Agency for Health and Food Safety (AGES) again inspected the site for issuance of a permanent Manufacturer’s Authorization. Before commissioning the site, the authority had already carried out an initial inspection at the end of 2021, which resulted in a temporary Manufacturer’s Authorization for two years, as is customary in Austria.

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announces additional investments as part of its long-term dedication to customer partnerships. Vetter’s extensive 40+ years of experience in aseptic filling and packaging shows a consistent desire for sustainable growth and corporate development. The pharmaceutical service provider plans with future-driven considerations to meet its long-lead goals for continued expansion and customer satisfaction.

Vetter, one of the world's leading Contract Development and Manufacturing Organizations (CDMO), is consistently pursuing improvements to its sustainability strategy. The globally-operating company released its second-annual sustainability report. For the first time, the pharmaceutical service provider headquartered in Ravensburg, Germany, also reports its Scope 3 emissions and shows its CO2 balance according to the requirements of the international Greenhouse Gas Protocol. Adding to its dynamic growth, the company was able to significantly reduce electricity consumption and CO2 emissions per euro of gross value added compared to the previous year. By 2029, the total emissions in relation to gross value added are to be reduced by ten percent compared to the base year 2019.

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), continues to drive the expansion of capacities and services for the provision of clinical trial materials: With the implementation of additional equipment for aseptic production and the expansion of storage capacities at the clinical site in Rankweil, Austria, the company is responding to increasing market demand. By the end of 2021, Vetter’s production in Rankweil was up and running, and 17 customer projects have already been won.

With the increasing drug development for novel therapeutics, a growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners to help meet the demand for complex fill and finish solutions. And, while the stages of early drug development are challenging, Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO) is committed to addressing this challenge by offering comprehensive expert manufacturing services for clinical trials and supporting their customer products path to commercialization. A testament to this commitment is evidenced by the success of its Skokie facility which has already contributed to bring five new customer products to market since it began full operations in 2011, with another four expected to launch in the next months.

Vetter, a globally leading contract development and manufacturing organization (CDMO), announced the commissioning of a new warehouse designed to help meet increasing customer market supply demands. With a total investment of approx. 20 million euros, the new fully automated building provides storage space for materials with high-stock turnover rates such as packaging components and thus optimizing the company’s logistical infrastructure. In addition, valuable capacity will be freed up in the existing warehouse.

With the realization of the first successful customer fills, Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has reached another milestone at its new clinical manufacturing facility in Rankweil, Austria. Further batches are already planned, and more customer projects are in the business pipeline. In addition, the site is being expanded to optimize processes and increase production capabilities.

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has received the manufacturing authorization for its new site in Rankweil, Austria. As a result of the successful inspection held by the responsible national regulatory authority, the Austrian Agency for Health and Food Safety (AGES), the site can now support clinical development projects of international pharmaceutical and biotech companies. The service provider had purchased the approximately 10,000 square meters manufacturing facility in 2020.

Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations (CDMOs), announced today that their strategic collaboration has taken key steps forward. The companies have further strengthened the established framework for their alliance and set up a governance structure, as well as implemented guidelines for their joint approach across functions. In parallel to starting their first joint client projects, they are also working closely on existing projects and related topics.